• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <0.01 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit proliferation/survival of IEC‑18 rat small intestinal epithelial cells. The ED    ₅₀ for this effect is 0.7-2.8 μg/mL.

• Source

  Mouse myeloma cell line, NS0-derived Gln67-Ala528, with a C-terminal 6-His tag

• Accession #

• N-terminal Sequence    
  Analysis

  No results obtained: Gln67 predicted, sequencing might be blocked

• Predicted Molecular Mass

  51.9 kDa

• SDS-PAGE

  80-90 kDa, reducing conditions

Background: DCBLD2/ESDN

DCBLD2 (discoidin, CUB, and LCCL domain containing protein 2), also known as CLCP1 and ESDN, is a 100-130 kDa glycoprotein that bears structural resemblance to the Neuropilin family of molecules. Mature human DCBLD2 is a type I transmembrane protein that consists of a 462 amino acid (aa) extracellular region (ECD), a 21 aa transmembrane segment, and a 226 aa cytoplasmic domain (1, 2). Within the ECD, human DCBLD2 shares approximately 88% aa sequence identity with mouse and rat DCBLD2. Alternative splicing generates an isoform that contains a 14 aa insertion in the cytoplasmic domain. DCBLD2 is expressed on vascular smooth muscle cells (VSMC), particularly in regions of arteriosclerosis and vascular injury (2, 3). It is up‑regulated on PDGF-BB stimulated VSMC and inhibits PDGF‑BB induced VSMC proliferation and migration (2‑4). It is also expressed on platelets and inhibits clot formation in a zebrafish model of thrombosis (5). Compared to normal tissue, DCBLD2 expression is down‑regulated in some gastric and neuroendocrine tumors but is up‑regulated in some metastatic lung cancers (1, 6, 7). It can be tyrosine phosphorylated in response to EGF R signaling and can inhibit colony formation and tumor cell invasiveness (6, 8, 9). Its direct association with Semaphorin 4B induces DCBLD2 degradation (10).

• References:

1. Koshikawa, K. et al. (2002) Oncogene 21:2822.

2. Kobuke, K. et al. (2001) J. Biol. Chem. 276:34105.

3. Sadeghi, M.M. et al. (2007) Am. J. Transplant. 7:2098.

4. Guo, X. et al. (2009) J. Biol. Chem. 284:29376.

5. O’Connor, M.N. et al. (2009) Blood 113:4754.

6. Kim, M. et al. (2008) Mol. Cancer Res. 6:222.

7. Hofsli, E. et al. (2008) Br. J. Cancer 99:1330.

8. Chen, Y. et al. (2007) Proteomics 7:2384.

9. Orso, F. et al. (2008) FASEB J. 22:2702.

10. Nagai, H. et al. (2007) Oncogene 26:4025.

• Long Name:

  Discoidin, CUB and LCCL Domain Containing 2/Endothelial and Smooth Muscle Cell-derived Neuropilin-li

• Entrez Gene IDs:

  131566 (Human); 73379 (Mouse); 155696 (Rat)

• Alternate Names:

  CLCP1; CLCP11700055P21Rik; CUB, LCCL and coagulation factor V/VIII-homology domains protein 1; DCBLD2; discoidin, CUB and LCCL domain containing 2; discoidin, CUB and LCCL domain-containing protein 2; Endothelial and smooth muscle cell-derived neuropilin-like protein; ESDN; ESDNcoagulation factor V/VIII-homology domains protein 1